Researchers found that TMAO is more abundant in tumors with an activated immune microenvironment and that TMAO can enhance CD8+ T-cell-mediated antitumor immunity by inducing pyroptosis of tumor cells through activation of ER stress kinase PERK 97. The gene discussed is CD8A; the disease is neoplasm.